It has been demonstrated that CAR-T cells expressing anti-CD33 and anti-CD3, and anti-CD22 and anti-CD33 CARs, have strong antitumor effects in patients with leukemia and lymphoma [145,146,147]. Here, CD33 is linked to lymphoma.